This study is testing two medications, Ticagrelor and Cilostazol, for treating a type of stroke called large-vessel ischemic stroke. This stroke happens when a big blood vessel in the brain is blocked. Participants are randomly given either ticagrelor or cilostazol shortly after their stroke. Ticagrelor starts with a 180 mg dose, then 90 mg twice daily for 90 days. Cilostazol starts with a 200 mg dose, then 100 mg twice daily for 90 days. Doctors will check how the medicine affects stroke recovery using tests like NIHSS (a stroke severity scale) and mRS (a scale of daily living ability). They also watch for side effects, like bleeding. Over the 90-day study, patients will have several brain scans and heart checks. To join, participants must be 18-75 years old and have their first large-vessel ischemic stroke. People with other serious health issues or certain medical histories cannot join.

• Study lasts 90 days with multiple check-ups and tests.
• Participants will take daily medication and have regular health assessments.
• Potential risks include medication side effects, primarily bleeding.